Sentence examples for m of unlabeled from inspiring English sources

Frozen sections of 10 μm (Cryo-Star HM 560 M; Microm, Walldorf, Germany) were mounted on Superfrost plus slides (Menzel, Braunschweig, Germany) and incubated with 10−10 M 111In-DTPA-octreotide with and without an excess (10−6 M) of unlabeled octreotide.

Hence, a molar solution was prepared and added to the artificial plasma to achieve a final concentration of either 30 or 300 μ m of unlabeled corticosterone.

The distribution of the radiolabeled GRs was also explored in the presence of 25 μ m of unlabeled digoxin, which was dissolved in warmed CSF.

The distribution of [H]corticosterone was also significantly reduced in the hypothalamus and cerebellum in the presence of 300 μ m, but not 30 μ m, of unlabeled cortisol.

The distribution of [H]corticosterone in the hypothalamus and cerebellum was significantly decreased in the presence of 300 μ m of unlabeled cortisol compared with wild-type controls (P = 0.017 and P = 0.002, respectively, one-way ANOVA, vascular space corrected).

Interestingly, the distribution of [H]cortisol in the hypothalamus and cerebellum was actually increased in the presence of 300 μ m of unlabeled corticosterone, but the distribution was not changed in any other brain region.

The 30 μ m concentration of unlabeled cortisol or corticosterone was previously used to saturate binding of GR in vitro (28– 30) but does not guarantee binding of saturation sites in situ.

The %AD is corrected for unspecific binding determined by blocking studies in which 10−6 M of the unlabeled agonist or antagonist was added.

The LNA-modified mmu-miR-709 and mmu-miR-705 detection probes were labeled with [ α S]-dATP (GE Healthcare, USA), using the Terminal Transferase Labeling Kit (Roche, Germany) according to the manufacturer's instructions, with minor modifications: a 1 50 dilution (0.5 μ M) of the unlabeled LNA-modified detection probe, 1 m C i/ m l α S-dATP and no UTP were used in the reaction mixture.

Specificity of W-box binding was shown by competition assays using 250-fold (W-box) and 500-fold (W-box; M-3, M-7) excess of unlabeled probes.

This serum dilution was then tested by RIP in which serum was incubated with 125I GAD65 or 125I GAD67 in the presence of five 10-fold dilutions of unlabeled GAD65 (1.6×10−11 M–1.6×10−7 M) or GAD67 (1.7×10−11 M–1.7×10−7 M) or assay buffer only.